前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.     

2019年广东省480例登革热住院患者的流行病学和临床特征分析

目的:分析2019年广东省登革热住院患者的流行病学和临床特征,为登革热的临床诊治及人群防治工作提供参考依据。方法:回顾性分析2019年1月4日至10月31日广州医科大学附属市八医院收治的480例登革热住院患者的一般资料、实验室检查资料、临床表现及预后,对登革热患者的临床特点和发病特征进行描述性分析。结果:480例登革热...     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.     

盐酸氨溴索注射液联合雾化吸入治疗急性加重期慢阻肺临床研究

目的观察盐酸氨溴索注射液静脉输注联合布地奈德混悬液、异丙托溴胺溶液雾化吸入在慢性阻塞性肺疾病急性加重期患者的临床疗效。方法收集我院2008年1月-2012年8月120例慢性阻塞性肺疾病急性加重期住院患者,随机分为2组：试验组在基础治疗原则上加入盐酸氨溴索注射液（沐舒坦）30mg静脉输注、布地奈德混悬液（普米克令舒）2mg与异丙托溴胺溶液（爱全乐）雾化吸入治疗,氧流量6—8L／min,持续20～30min,2杉日,7d为一疗程,共60例患者。对照组常规治疗,包括静脉应用抗生素、解痉平喘、持续低流量吸氧（1—2L／min）、祛痰等。共60例。治疗前后比较两组患者临床症状变化、临床体征变化、动脉血气分析、最大呼气流速的变化等因素,评价三联药物对COPD患者急性加重期的临床疗效。结果两组患者经过治疗后,临床症状如咳痰、肺部哆音、咳嗽、气促等评分。动脉血气分析、最大呼气流速等均较治疗前有显著性改善,具有明显统计学差异（P〈0．05）。经过治疗后实验组临床症状（咳痰、咳嗽、肺部哆音、气促）评分、最大呼气流速、动脉血气分析均对照组有显著性改善,具有明显统计学差异（P〈0．05）。结论盐酸氨溴索注射液静脉输注联合布地奈德混悬液、异丙托溴胺溶液雾化吸入能显著改善COPD患者急性加重期的临床疗效。     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.     

广州278例新型冠状病毒肺炎患者的流行病学、临床特征及治疗分析

目的回顾性分析新型冠状病毒肺炎(COVID-19)患者的流行病学、临床特征及治疗情况,为COVID-19临床诊疗提供参考。方法选取2020年1月20日至2月10日广州市第八人民医院收治的278例COVID-19确诊患者作为研究对象,收集患者的一般人口学资料、流行病学资料、基础疾病、临床表现、实验室检查、胸部CT影像学资料、治疗及预后等资料进行分析。结果 278例患者中男性130例(46.8%),女性148例(53.2%),年龄(48.1±17.0)岁,20～69岁患者占88.8%,236例(84.9%)患者合并有基础疾病,普通型居多211例(75.9%),住院病死率0.4%(1/278)。病例来源以输入性病例为主(201例,72.3%),这其中武汉输入89例(占全部输入性病例的44.3%)。最常见的临床表现为发热(70.9%)和干咳(61.5%)。患者以白细胞正常(79.5%)或减少(16.5%)、淋巴细胞减少(33.5%)多见,部分患者血红蛋白(10.4%)和血小板(12.6%)减少,55.4%患者白蛋白水平降低,肝功能(丙氨酸转氨酶、天冬氨酸转氨酶)、肾功能(肌酐、尿素氮)指标无明...     

瑞舒伐他汀对脓毒性休克患者的血清乳酸水平的影响及其治疗疗效分析

目的:评估瑞舒伐他汀对脓毒性休克患者血清乳酸水平的影响及其临床疗效。方法:收集2014-05-2015-07期间入住我院ICU并确诊为脓毒性休克的66例患者,随机分入对照组和干预组。干预组38例,男24例,女14例;年龄21～80岁,平均(51.76±16.48)岁。对照组28例,男12例,女16例;年龄38～78岁,平均(52.86±14.56)岁。治疗组采用瑞舒伐他汀以及常规治疗,对照组仅采用西医常规治疗。疗效评估方法分别记录两组患者入院时以及入院后12、24、48 h血清乳酸浓度;分别于入院时和治疗7 d后时采用APACHEⅡ评分标准对两组患者进行评估。结果:干预组及对照组的年龄、性别构成、原发病构成以及入院时的血清乳酸水平和APACHEⅡ评分差异无统计学意义(P0.05)。与对照组相比,干预组能显著降低脓毒性休克患者入院后12、24、48 h的血清乳酸浓度(P0.05);与入院时相比,两组患者的APACHEⅡ评分均降低;但治疗7 d后,干预组的APACHEⅡ评分较对照组降低更为显著(P0.05)。结论:瑞舒伐他汀能明显降低脓毒性休克患者的血清乳酸水平和APACHEⅡ评分,具有较好的近期疗效。